Chapter 777

Yang Rui is not a free talker. In fact, because he is young and a student, he purposely pursues a rigorous attitude in the laboratory. No matter how exaggerated his words are, there are traces to follow and try his best to realize them.

Therefore, when Yang Rui said that he wanted to get rid of iron and ketone as soon as possible, Xu Zhengping was not very good. He said, "director Yang, let's go back and find out about the situation first. I haven't seen iron and ketone before."

"What director Xu said is." Wang Sisheng also had an exciting reaction. It's a matter of consuming resources, and it's a great resource.

Yang Rui thought for a while and said, "if you don't agree, I'll give it to Huarui laboratory. Huarui is a company in Hong Kong. If thalassemia occurs in Hong Kong, there are some in Hong Kong."

In the last question, Yang Rui looks at Yong Xiaodong.

Yong Xiaodong pursed his mouth, trembled his emaciated figure, and said: "there is indeed thalassemia in Hong Kong, but the level of pharmaceutical companies in Hong Kong..."

"As long as there's a lab, right?"

"Yes... I hope we can wait." Yong Xiaodong is a clinician, not a researcher. He doesn't know the complicated process of making medicine, but he knows the time required for a new drug to be launched.

Most of the drugs can be made in 10 years, which is lucky.

For those simple compounds, when you are given the synthesis formula and key points, the experimental dog can do it several times. But if there is no formula and key points, ha ha, the dead brain cells of synthetic chemistry majors can be gathered together and strangle 300 bullshit undergraduates at a time.

Different from the normal researchers who retreat from the hairline of pharmaceutical companies, Yang ruiman's brain is full of formulas and key points for the synthesis of various compounds.

80 The pharmaceutical patents in the's and '90s are basically invalid after 2000 or 2010, and the domestic generic drug companies do not know how many copies they have made. For example, today's most popular cephalosporins, whether cefaclor or cefaclor, can be found not only in papers and various monographs, but also on the Internet. When Yang Rui was reading, he could meet them at any time.

Of course, there are too many domestic companies that copy them, so that the price of raw materials with tens of thousands of yuan per kilogram will plummet to thousands or even hundreds of yuan after 2000

In Yang Rui's eyes, the synthesis of deferonone is no secret. However, he is engaged in biology after all, and he is not very proficient in chemical synthesis, It is estimated that it will take some time to practice.

"Let me ask Huarui Hong Kong. Desferridone is a kind of medicine. If it is made, it should be profitable. They should consider it. " Yang Rui didn't say anything so as not to leak too much information.

On the contrary, Yong Xiaodong believed Yang Rui more. Lian said hastily, "yes, if we produce iron ketone, we can definitely make money. There are still a lot of patients who need it. We Chinese are relatively poor, but there are still rich people in Southeast Asian countries, right?"

"Look, if you can do it, even if you don't earn much, it will be a sum of money in the long run." Yang Rui looked at Xu Zhengping and said, "if we do it, we will have the guarantee of scientific research funds in the future."

"Forget it, even if the results in our laboratory have profits, they should be handed over to the school, otherwise, the school's funding will not be considered in the future." Xu Zhengping was afraid that Yang Rui would want the ion channel laboratory to do it, so he would have to devote all his time and energy to it.

Even if it's the basic work of biology, Xu Zhengping doesn't have to point to interacting proteins to live on. Mutual eggs or mutual ostrich eggs can also be studied for a lifetime. But the pharmaceutical industry is too far away from him.

Xu Zhengping's age and qualifications do not allow him to turn to other fields.

Yang Rui can guess Xu Zhengping's answer, although a little disappointed, but also in reason, just nodded and said: "since director Xu does not agree, that's it."

Yong Xiaodong didn't care who did it. Seeing the two men finished, he said, "director Yang, I have some information that you can show to the people of Hong Kong."

With these words, Yong Xiaodong takes Yang Rui and others to the office, starts to search information from various filing cabinets, and piles up the things he finds in the middle of the room.

After a while, the room piled up a chair high hill bag.

Yang Rui picked up several pieces of information and read them.

Most of them are clinical records made by Yong Xiaodong. In addition, there seems to be some introduction and related information about thalassemia.

All of these, except for a few mimeographs and newspaper clippings, are mostly hand copied.

The handwriting of all the data is the same, but if you look carefully, you can still see the weak difference. If you analyze the paper again, you can recognize that these records may last for a long time."I have been doing research on thalassemia for more than ten years. Since the appearance of deferoxamine, I started to do it, the first batch in China." Yong Xiaodong noticed Yang Rui's expression, reluctantly laughed and said: "to be honest, I have studied thalassemia for so many years, but I have no achievements. If there is no hope, I am going to sort out the data, publish a few more papers and stop."

Yang Rui was stunned and didn't speak.

"Useful or not, that's all." Yong Xiaodong got dust all over his body, went to the door to take a picture, then came back and said, "when desferrioxamine just came out, in the 1960s, we got a piece of information. At that time, the colleagues in the Department of Hematology were boiling and said that the poor people could be saved. I was assigned by my superiors to join the working group of the poor, responsible for the amount of research and thorough information. The working group also contacted the pharmaceutical factory and made generic drugs. Later, after the clinical use of deferoxamine, it was really effective. In the past, intermediate patients could only live to 20 or 30 years old, and after treatment, their life expectancy was extended by 10 or even 20 years, The improvement of quality of life is even greater. Some people can still live normally now, and patients with severe thalassemia can be regarded as having outstanding curative effect. However, from more than ten years ago to now, our work has produced limited changes... Without new drugs, even if we are very busy, we can solve some small problems at most, We can't even remove more complications... "

Yang Rui nodded slightly. He could understand Yong Xiaodong's powerlessness.

Like most genetic diseases, thalassemia treatment is very simple, and clinicians are difficult to come up with better treatment.

Blood transfusion to prolong life, iron removal to slow down complications. This program was established in the 1960s, and it will not change much in the next 16 years. In the middle, it has changed from splenectomy to stem cell transplantation, but the basic idea is still the same.

Without new drugs, no good clinician can solve the disease better.

If there is a perfect iron removal agent, which does not cause side effects or serious side effects, and the price is not expensive, thalassemia can be controlled.

Because the cause of thalassemia premature death, skeletal deformity, are the body's excessive iron accumulation.

However, the world is always so imperfect.

Only in an imperfect world can we make our existence valuable.

Yang Rui held Yong Xiaodong and said, "I will take a good look at your information. At that time, I will copy it and give it to Hua Rui, and then send the original information back to you."

"If you copy it, will it cost too much..." Yong Xiaodong is also willing to leave the original materials. For him, the records of more than ten years in a row are not only important memories, but also important resources.

"Hong Kong people have money," Yang said with a smile

"Don't scare people." Yong Xiaodong was very concerned and said, "by the way, do you know the orphan drug system in the United States?"

After thinking for a while, Yang Rui came to realize: "is that aofen?"

Aofen is the literal translation of orphans, and in Yang Rui's familiar environment, orphan drugs have been widely known as rare drugs.

Yong Xiaodong nodded and said, "yes, English is reading ofen. Thalassemia should be a rare disease. Therefore, drugs for thalassemia, such as deferrone, should be drugs for rare diseases. They are in line with a bill of the United States called the rare diseases Drug Act, which is said to be a preferential policy. I'll check it again, and I'll tell you at that time. It's also a good thing. "

"You're talking about the ODA approved by the United States last year. It's really a big preferential policy." Yang Rui knew more about this and said casually: "if the application for rare disease drugs is approved, there should be seven years of market monopoly, tax relief for development costs and application fees..."

"Yes, that's it. Does it work?"

"Useful is of course useful."

"But it doesn't work?"

"I'm afraid that won't be the deciding factor." Yang Rui smiles bitterly. If it is after 2000, the development of drugs for rare diseases is indeed profitable, and some drugs can even become "blockbusters" with annual sales exceeding 1 billion US dollars. For example, elaprase, the treatment of Hunt's syndrome, has only 2000 patients in the world, but the annual treatment cost of each patient is 37. 50000 dollars, which means elaprase's annual sales easily exceed 100 million. Gleevec, a treatment for chronic myeloid leukemia, is well-known in China. The monthly cost is 20000 yuan, and the minimum annual cost is 70000 yuan if the charity plan is added.

However, Americans can't afford $370000, or $10000 a year in fixed medical expenses. They rely on the help of insurance companies, the national aid and rescue system, and non-profit patient assistance agencies.

And in the 1980s, at least 84 years now, Americans didn't get these things. Their insurance companies won't pay for high priced drugs for patients with rare diseases, so patients with rare diseases can't afford high priced drugsTherefore, at the beginning of the establishment of the rare diseases act, there were not many drugs for rare diseases. The era that really benefited patients with rare diseases was the era after insurance companies solved the problem of high price drugs.

Deferrone is special because it can not completely replace deferoxamine, which means deferrone is a rare drug with alternative products.

Rare diseases mean fewer patients, fewer patients mean lower sales of drugs, and alternative products mean lower prices of drugs.

If the sales volume is low and the price is low, how can we make money.

What's more, Yang Rui's original intention of developing deferoxane was to reduce the burden of patients with thalassemia and solve the problem that deferoxamine was too expensive.

"Hong Kong Huarui company does not have to point to making money." Yang Rui said slowly: "I'll contact Huarui's laboratory first to see if we can make iron ketone. As for the price, we should be proficient in clinical trials in advance and the process of drug sales. Rare drugs do have advantages in this respect. "

"Saving a person's life is better than building a seven level floating butcher..." Yong Xiaodong holds Yang Rui's hand tightly. He has been treating thalassemia for 20 years, and he has seen the patients with thalassemia for 20 years, and the impact on his heart is self-evident.

Yang Rui shakes Yong Xiaodong's hand and leaves without giving him any commitment. This is not a problem that can be solved by commitment.

……